Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammationAna Martı́nez, Mercedes Alonso, Ana Castro et al.|Medicinal Research Reviews|2002Cited by 334
Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's DiseasePilar Muñoz-Ruiz, Ana Martı́nez, Laura Rubio et al.|Journal of Medicinal Chemistry|2005Cited by 221
Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChED. A. Alonso, Ana Martı́nez, Isabel Dorronsoro et al.|Bioorganic & Medicinal Chemistry|2005Cited by 157
SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives: Exploration of Structural Requirements for Glycogen Synthase Kinase 3 InhibitorsAna Martı́nez, Francisco J. Moreno, Mercedes Alonso et al.|Journal of Medicinal Chemistry|2005Cited by 128
Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?Isabel Dorronsoro, Ana Martı́nez, Ana Castro|Expert Opinion on Therapeutic Patents|2002Cited by 52